Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

vTV’s Alzheimer’s and type 2 diabetes therapy has some support for positive data but skepticism remains, says GlobalData

In light of another setback in the Alzheimer’s disease (AD) drug development field, with the failure of Roche and AC Immune’s antitau antibody, all eyes will be on results for vTv Therapeutics’ azeliragon for AD and type 2 diabetes; William Newton, Pharma Writer for the Investigative News team at GlobalData, offers his view: “Although azeliragon […]
Read more

Amyotrophic lateral sclerosis set to increase to 65,900 cases in the 8MM in 2029 due to aging populations, says GlobalData

The diagnosed prevalent cases of amyotrophic lateral sclerosis (ALS) in the eight major markets (*8MM) is expected to increase from 57,800 cases in 2019 to 65,900 cases in 2029, at an annual growth rate (AGR) of 1.41%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Amyotrophic Lateral Sclerosis: Epidemiology Forecast to […]
Read more

Positive CHMP opinion on Baricitinib in atopic dermatitis positions it to take on Dupixent, says GlobalData

Eli Lilly’s baricitinib, marketed as Olumiant in rheumatoid arthritis, has received a recommendation of approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for moderate to severe adult atopic dermatitis (AD) patients, positioning the drug to take on Sanofi and Regeneron’s juggernaut Dupixent (dupilumab), says GlobalData, a leading data […]
Read more

October FDA Advisory Committee meeting on Alkermes’ ALKS-3831 has mixed expectations on weight gain data discussion

Alkermes’ schizophrenia/bipolar disorder candidate ALKS–3831 weight gain data will be at the forefront of a 9 October FDA Advisory Committee (AdCom) meeting, but how the panel members will evaluate it is up for debate, as reported by William Newton, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Newton comments: “The AdCom will question whether ALKS–3831, which is a combination of an opioid antagonist […]
Read more

SGLT-2 inhibitors likely to be primary growth drivers of branded heart failure treatment market, says GlobalData

Eli Lilly and Boehringer Ingelheim’s (BI’s) Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) are expected to drive heart failure (HF) market growth and achieve high uptake as cardiologists become more familiar with the sodium-glucose cotransporter-2 inhibitors (SGLT-2I) class, says GlobalData, a leading data and analytics company. At the recently concluded European Society of Cardiology (ESC) Congress […]
Read more

Amarin’s positive ESC data may boost Vascepa’s EU marketing efforts amid US generic entry threat

Amarin Corporation recently presented final results from the EVAPORATE trial in which Vascepa (icosapent ethyl) reduced patients’ coronary plaque by 17% compared to placebo following 18 months. The newly presented results can be leveraged to reinforce physician education and maximize revenue opportunity in the EU where Amarin is not facing imminent market exclusivity loss, according to GlobalData, a […]
Read more

More public pharma and CMOs took PPP COVID-19 small business loans

At least 99 publicly owned pharma companies and contract manufacturing organizations (CMOs) – many with substantial market value and access to capital markets – were approved to receive PPP loans that were intended to help small businesses in the US to pay workers during the COVID-19 pandemic, a GlobalData analysis of a partial release of information by the Small Business Administration (SBA) shows. PPP (paycheck protection program) loans are a US federal government initiative. Fiona Barry, Associate Editor of GlobalData PharmSource, […]
Read more

Despite crowded CKD-HPT market, Shield Therapeutics remains committed to PT20 following positive Phase IIb results

Phase IIb results were published in July for Shield Therapeutics’ oral iron-based phosphate binder PT20 for the treatment of hyperphosphatemia (HPT) in dialysis-dependent chronic kidney disease (CKD) patients. Although the CKD-HPT market has several marketed treatments available, PT20 has the potential to capture a slice of the HPT market by targeting dialysis-dependent patients who are […]
Read more

Roche’s Ocrevus confirm its strong position of highly efficacious drug in the MS landscape

Following the publication of new positive data from the Phase IIIb CASTING trial of Roche’s Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS); Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Roche’s Ocrevus has several notable clinical attributes that support its strong market uptake, including high […]
Read more

Key players in IBD space engage effectively with Japanese patients through well-established digital strategy, says GlobalData

In Japan, the treatment landscape for inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is mature and encompassing many conventional therapies as well as novel therapies including biologics and a small molecule. With the increasing competition from biosimilars and the late-stage pipeline drugs, key players with novel therapies are offering comprehensive […]
Read more
1 … 79 80 81 82 83 … 108